{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:54:20Z","timestamp":1758992060312,"version":"3.40.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ophtha.2018.12.004","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T07:02:48Z","timestamp":1550818968000},"page":"e22-e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Re: Hughes et\u00a0al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424)"],"prefix":"10.1016","volume":"126","author":[{"given":"Sue","family":"Lightman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-859X","authenticated-orcid":false,"given":"Rachael","family":"Niederer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3994","authenticated-orcid":false,"given":"Srilakshmi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-1641","authenticated-orcid":false,"given":"Oren","family":"Tomkins-Netzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika Marie","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-8622","authenticated-orcid":false,"given":"Beatrice","family":"Peebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.12.004_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","article-title":"Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Hughes","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2018.12.004_bib2","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ophtha.2018.12.004_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","article-title":"Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis","volume":"151","author":"Kalinina Ayuso","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2018.12.004_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","article-title":"Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study","volume":"120","author":"Gregory","year":"2013","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2018.12.004_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/acr.22627","article-title":"Using the effects of youngsters' eyesight on quality of life questionnaire to measure visual outcomes in children with Uveitis","volume":"67","author":"Angeles-Han","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.ophtha.2018.12.004_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12969-017-0189-6","article-title":"Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis","volume":"15","author":"Sen","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"17","key":"10.1016\/j.ophtha.2018.12.004_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ophtha.2018.12.004_bib9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0272989X18798833","article-title":"Future directions for cost-effectiveness analyses in health and medicine","volume":"38","author":"Neumann","year":"2018","journal-title":"Med Decis Making"},{"issue":"34","key":"10.1016\/j.ophtha.2018.12.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technol Assess"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018327271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018327271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T07:03:02Z","timestamp":1550818982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018327271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0161642018327271"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.004","relation":{},"ISSN":["0161-6420"],"issn-type":[{"type":"print","value":"0161-6420"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Hughes et\u00a0al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.043","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}